Lotte Biologics boosts its global contract development and manufacturing organization (CDMO) growth by establishing facilities in North America and Asia, and focusing on cutting-edge antibody-drug conjugate (ADC) technologies.

Lotte Biologics boosts its global contract development and manufacturing organization (CDMO) growth by establishing facilities in North America and Asia, and focusing on cutting-edge antibody-drug conjugate (ADC) technologies.

Lotte Biologics Expands Global Presence as a Leading CDMO Company

Lotte Biologics, a South Korean biotech company under the leadership of CEO James Park, is making significant strides in the global Contract Development and Manufacturing Organization (CDMO) market. The company is accelerating its growth and increasing brand awareness by consistently participating in major global events.

In 2022, Lotte Biologics entered the global CDMO market with a significant move – the acquisition of Bristol-Myers Squibb’s biologics manufacturing facility in Syracuse, New York. This strategic acquisition has solidified Lotte Biologics as a competitive global CDMO, boasting world-class manufacturing quality. The Syracuse Bio Campus now serves as a North American hub, while complementary facilities in Asia enable broader market reach.

Lotte Biologics has invested approximately USD 100 million into its Syracuse Bio Campus to establish advanced ADC production infrastructure. This investment has enabled production scale-up to 1,000L capacity and next-generation ADC modalities. The company has already signed its first ADC production contract and aims to start production within the current year.

This strategic dual manufacturing base approach strengthens partnerships and client acquisition by leveraging high-quality manufacturing standards across continents. Lotte Biologics' entry and aggressive scale-up from 2022 onward have positioned it as a disruptive player in the modality-specialized CDMO landscape.

Moreover, Lotte Biologics is advancing its technology differentiation through its proprietary ADC platform, SoluFlex Link™. The company is pursuing strategic collaborations with leading domestic and global biotech companies, aiming to create integrated, reliable services by combining mutual strengths through co-prosperity.

Looking forward, Lotte Biologics is constructing a large-scale commercial bio campus in Songdo, Korea, with the first plant scheduled to begin operations in 2027. This Songdo site will function as a Large-scale Production Base, complementing the overall manufacturing network. The company has secured contract manufacturing deals with global pharma companies based in the U.S., publicly listed biotechs, and European firms. In April, Lotte Biologics signed a production agreement with an Asia-based biotech company for an ADC clinical candidate.

Lotte Biologics delivers end-to-end solutions covering clinical development through commercial manufacturing. The quality competitiveness and global production track record of the Syracuse facility are core assets of the company, and these capabilities are playing a key role in securing new contracts. The company can be connected through various platforms including YouTube, LinkedIn, Twitter, Facebook, Email, and Print.

In summary, Lotte Biologics' current expansion strategy hinges on dual manufacturing hubs in Syracuse, U.S., and South Korea, significant capital investment, leveraging acquisition of BMS’s Syracuse facility, growing the client base through quality competitiveness and specialized next-generation ADC modalities, and achieving first ADC production contracts and targeted production start in 2025. This positions Lotte Biologics as a leading global CDMO focused on the development and manufacturing of complex next-gen biologics, particularly ADCs.

In the continuation of its expansion, Lotte Biologics aims to strengthen its position in the global biotech industry by fostering partnerships in the finance sector, attracting investments for technological advancements to further improve its business operations and manufacturing quality. The company's strategic acquisition of Bristol-Myers Squibb’s biologics manufacturing facility in Syracuse, New York, has also opened doors for increased collaborations in the technology domain, as the facility now serves as a North American hub.

Read also: